---
title: "金斯瑞生物科技股份有限公司 (01548.HK)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/01548.HK.md"
symbol: "01548.HK"
name: "金斯瑞生物科技股份有限公司"
industry: "生命科学工具与服务"
---

# 金斯瑞生物科技股份有限公司 (01548.HK)

| Item | Detail |
|------|--------|
| Industry | 生命科学工具与服务 |
| Location | 港股市场 |
| Website | [www.genscript.com](https://www.genscript.com) |

## Company Profile

金斯瑞生物科技股份有限公司是一家主要从事生产及销售生命科学研究产品及服务的投资控股公司。该公司通过五个分部开展业务。生命科学服务及产品分部提供全面的研究服务及产品。生物制剂开发服务分部以一个综合平台提供全面服务，旨在帮助生物制药及生物技术公司加快治疗性抗体及基因、细胞疗法产品的开发。工业合成生物产品分部通过使用基因工程建构非病源微生物株，提供工业酶开发和生产。细胞疗法分部发现和开发用于治疗液体及固体肿瘤的 CAR-T 疗法。经营管理分部主要为其他分部提供共享服务。该公司主要在中国国内和海外市场开展业务。

## Financial Score

> *Longbridge Financial Score™ — Proprietary multi-factor rating model by [Longbridge](https://longbridge.com). This score is independently calculated by Longbridge and is not affiliated with any third-party rating agency.*
> Updated: 2026-02-21T04:30:11.000Z

**Overall: B (0.34)**

**Industry**: Life Sciences Tools and Services

| Metric | Value |
|--------|-------|
| Industry Ranking | 6 / 14 |
| Industry Median | B |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Mid - The company has stable operation of a large-cap stock and the high return of a small-cap stock.

### Score Analysis

**Style Score**: 

#### Growth Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 81.62% |  |
| Net Profit YoY | 1851.58% |  |

#### Value Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| P/B Ratio | 0.76 |  |
| Dividend Ratio | 0.00% |  |


**Size Score**: 

#### Market Cap Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 26.30B |  |

#### Revenue Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue | 6.45B |  |


**Multi Score**: B

#### Profit Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 0.16% | D |
| Profit Margin | 375.74% | A |
| Gross Margin | 61.81% | A |

#### Growth Score: A

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 81.62% | A |
| Net Profit YoY | 1851.58% | A |
| Total Assets YoY | 63.96% | A |
| Net Assets YoY | 143.64% | A |

#### Cash Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| Cash Flow Margin | 26.61% | C |
| OCF YoY | 81.62% | A |

#### Operating Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| Turnover | 0.19 | D |

#### Debt Score: A

| Indicator | Value | Rating |
|-----------|-------|--------|
| Gearing Ratio | 18.65% | A |


```chart-data:radar
{
  "title": "Longbridge Financial Score - 金斯瑞生物科技股份有限公司",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Profit",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "0.16%",
          "rating": "D"
        },
        {
          "name": "Profit Margin",
          "value": "375.74%",
          "rating": "A"
        },
        {
          "name": "Gross Margin",
          "value": "61.81%",
          "rating": "A"
        }
      ]
    },
    {
      "name": "Growth",
      "grade": "A",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "81.62%",
          "rating": "A"
        },
        {
          "name": "Net Profit YoY",
          "value": "1851.58%",
          "rating": "A"
        },
        {
          "name": "Total Assets YoY",
          "value": "63.96%",
          "rating": "A"
        },
        {
          "name": "Net Assets YoY",
          "value": "143.64%",
          "rating": "A"
        }
      ]
    },
    {
      "name": "Cash",
      "grade": "B",
      "indicators": [
        {
          "name": "Cash Flow Margin",
          "value": "26.61%",
          "rating": "C"
        },
        {
          "name": "OCF YoY",
          "value": "81.62%",
          "rating": "A"
        }
      ]
    },
    {
      "name": "Operating",
      "grade": "D",
      "indicators": [
        {
          "name": "Turnover",
          "value": "0.19",
          "rating": "D"
        }
      ]
    },
    {
      "name": "Security",
      "grade": "A",
      "indicators": [
        {
          "name": "Gearing Ratio",
          "value": "18.65%",
          "rating": "A"
        }
      ]
    }
  ]
}
```

### Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
|------|------|--------|--------|-----------|----------|------|--------|
| 01 | 药明康德 (HK.2359) | A | A | C | B | B | B |
| 02 | 药明生物 (HK.2269) | B | B | D | A | B | B |
| 03 | 药明合联 (HK.2268) | A | A | B | B | B | B |
| 04 | 晶泰控股 (HK.2228) | D | A | E | A | C | B |
| 05 | 康龙化成 (HK.3759) | B | B | C | C | B | B |

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 1.08 | 1/15 | 1.54 | 1.35 | 1.12 |
| PB | 0.76 | 2/15 | 1.09 | 0.95 | 0.79 |
| PS (TTM) | 4.05 | 5/15 | 6.34 | 5.46 | 4.49 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2026-02-04T16:00:00.000Z

Total Analysts: **10**

| Rating | Count | Percentage |
|--------|-------|-----------|
| Buy | 8 | 80% |
| Overweight | 2 | 20% |
| Hold | 0 | 0% |
| Underweight | 0 | 0% |
| Sell | 0 | 0% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 12.03 |
| Highest Target | 26.29 |
| Lowest Target | 20.00 |

## References

- [Company Overview](https://longbridge.com/en/quote/01548.HK/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/01548.HK/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/01548.HK/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.